This expansion has been especially prominent in the field of multiple myeloma, a cancer of plasma cells, where researchers have identified B-cell maturation antigen (BCMA) as a highly promising therapeutic target due to its consistent expression on malignant plasma cells and limited presence on normal tissues (20, 21). Here, TNFRSF17 is linked to AL amyloidosis.